TABLE 4.
Outcome of patients with or without DREMM.
| Total n = 45 | No DREMM n = 18 | DREMM n = 27 | P-value | |
|---|---|---|---|---|
| Active ABMR, n (%) Subclinical/clinical (%/%) Time post-transplant, months, median (IQR) Associated TCMR, n (%) Chronic ABMR on subsequent biopsies, n (%) |
24 (53) 29/71 2.4 (0.5–11.7) 2 (8) 4 (17) |
5 (28) 40/60 1.2 (0.6–3.8) 0 (0) 1 (20) |
19 (70) 26/74 2.9 (0.5–12.1) 2 (11) 3 (16) |
0.005 0.61 0.62 1 1 |
| Follow-up, months, median (IQR) | 60.9 (24.7–92.2) | 54.5 (22.3–94.5) | 63.2 (29.5–90.9) | 0.95 |
| Death-censored graft failure, n (%) | 8 (18) | 0 (0) | 8 (30) | 0.01 |
| Death, n (%) | 16 (36) | 8 (44) | 8 (30) | 0.31 |
DREMM, donor-specific antibody targeting a repeated antibody-verified eplet mismatch; ABMR, antibody-mediated rejection; TCMR, T-cell mediated rejection.